title: Interleukin-17 inhibition in psoriatic arthritis.
abstract: Greater understanding of the underlying disease process has led to the development of targeted therapeutic agents and innovative strategies in the treatment of psoriatic arthritis (PsA). This report addresses novel medications targeting the T helper 17 cell pathway, specifically those inhibiting interleukin-17A and its receptor, and discusses their role as effective therapies in the management of PsA.
authors.affiliation: Western University, London, ON, Canada.
authors.forename: Tristan
authors.initials: T
authors.lastname: Boyd
authors.affiliation: Division of Rheumatology, Allergy and Immunology, Center for Innovative Therapy (CIT), University of California, La Jolla, CA, USA. akavanaugh@ucsd.edu.
authors.forename: Arthur
authors.initials: A
authors.lastname: Kavanaugh
mesh_terms: D000818:Animals; D000893:Anti-Inflammatory Agents / Q000009:adverse effects / Q000627:therapeutic use*; D015535:Arthritis, Psoriatic / Q000175:diagnosis / Q000188:drug therapy* / Q000276:immunology; D001688:Biological Products / Q000009:adverse effects / Q000627:therapeutic use*; D006801:Humans; D018836:Inflammation Mediators / Q000037:antagonists & inhibitors* / Q000276:immunology; D020381:Interleukin-17 / Q000037:antagonists & inhibitors* / Q000276:immunology; D058990:Molecular Targeted Therapy; D012074:Remission Induction; D015398:Signal Transduction / Q000187:drug effects; D016896:Treatment Outcome
chemical_list: D000893:Anti-Inflammatory Agents; D001688:Biological Products; D018836:Inflammation Mediators; D020381:Interleukin-17